x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:00:00

Emerging Directions in Biomarker-Directed Therapy for...

CME/CE ·

2024/12/30

Host: Alan Venook, MD The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and

en

00:00:00

Unmasking IgAN: From Suspicion to Timely Diagnosis

CME/CE ·

2024/12/30

Host: Jörg Latus, MD Guest: Chee Kay Cheung, MBCHB, MRCP, PHD Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways in disease pathophysiology. Join the experts for an exploration of these important clinical topics using a

en

00:00:00

AHA 2024 and Acoramidis: Impact on the Future of...

CME/CE ·

2024/12/27

Host: Mazen Hanna, MD New data from the ATTRibute-Cardiomyopathy open-label extension study were presented at AHA 2024. Join Dr. Mazen Hanna as he reviews the topline cardiovascular outcomes on the efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) and hear what this new treatment means for your clinical practice.

en

00:00:00

AHA 2024 and Acoramidis: Impact on the Future of...

CME/CE ·

2024/12/27

Host: Mazen Hanna, MD New data from the ATTRibute-Cardiomyopathy open-label extension study were presented at AHA 2024. Join Dr. Mazen Hanna as he reviews the topline cardiovascular outcomes on the efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) and hear what this new treatment means for your clinical practice.

en

00:00:00

Risk Assessment in Pulmonary Hypertension: Practice...

CME/CE ·

2024/12/20

Guest: Robert P. Frantz, MD, FACC Guest: Vallerie V. McLaughlin, MD Guest: Sonja Bartolomei, MD Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their care and quality of life. You’ll also discover changing practice trends and the latest evidence that may impact your practice.

en

00:00:00

Pulmonary Hypertension Management: Practice Trends...

CME/CE ·

2024/12/20

Guest: Vallerie V. McLaughlin, MD Guest: Victor Moles, MD Guest: Ioana Preston, MD The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. This activity presents the latest evidence and breaks down new approaches to the management of PH. Join our experts to find out how your daily practice will be affected.

en

00:00:00

Pulmonary Hypertension: Comorbidities With PAH and...

CME/CE ·

2024/12/20

Guest: Vallerie V. McLaughlin, MD Guest: Thomas Cascino, MD Guest: Bradley A. Maron, MD Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from left heart disease may further complicate diagnosis and treatment. Hear what the experts have to say about identifying and treating these patient populations.

en

00:00:00

Biologic Rationale for Targeting HER3 and Role in...

CME/CE ·

2024/12/17

Host: Pasi Antero Jänne, MD, PhD This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed

en

00:00:00

Overcoming EGFR Resistance With HER3-Directed ADCs

CME/CE ·

2024/12/17

Host: Helena Yu, MD This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug

en

00:00:00

Case Application: Patients With EGFRm Resistance Post...

CME/CE ·

2024/12/17

Host: Pasi Antero Jänne, MD, PhD Guest: Helena Yu, MD This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for

en

00:00:00

Expert Peer Discussion: Integrating Novel...

CME/CE ·

2024/12/17

Host: Pasi Antero Jänne, MD, PhD Guest: Helena Yu, MD This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for

en

00:00:00

Interprofessional Monitoring and Management of AEs...

CME/CE ·

2024/12/17

Host: Helena Yu, MD Guest: Pasi Antero Jänne, MD, PhD This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for

en

00:00:00

Case Application: Patients With EGFRm Resistance Post...

CME/CE ·

2024/12/17

Host: Helena Yu, MD Guest: Pasi Antero Jänne, MD, PhD This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for

en

00:00:00

Finally, I Can Take a Break from My Itch! Optimizing...

CME/CE ·

2024/12/16

Guest: Jörg Latus, MD Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These symptoms have the potential to significantly diminish patients’ quality of life by affecting sleep, mental health, and more. This activity reviews best practices for communicating with patients about symptoms and how to use shared decision-making strategies to develop personalized CKD-aP treatment

en

00:00:00

Advances in IgAN Care From Kidney Week

CME/CE ·

2024/12/13

Host: Jörg Latus, MD Guest: Sydney Tang, MBBS, MD In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPARTACUS, and the PROTECT open-label extension. Throughout this conversation, faculty also consider the anticipated updates to the KDIGO clinical guidelines.

en

00:00:00

Best Practices for Identifying, Diagnosing and...

CME/CE ·

2024/12/13

Host: John Russell, MD Guest: Noel Dasgupta, MD, FACC Guest: Sami Khella, MD Amyloidosis, often unrecognized, misdiagnosed, and either inappropriately treated or undertreated, is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. There are two prominent forms of amyloidosis misfolding of light chain proteins (AL amyloidosis) and transthyretin protein misfolding (ATTR amyloidosis). In this program,

en

00:00:00

The Weight of Recurrence: Navigating...

CME/CE ·

2024/12/06

Host: Brian Slomovitz, MD Guest: Robert L. Coleman, MD, FACOG, FACS In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this

en

00:00:00

Emerging and practice-changing directions in NSCLC...

CME/CE ·

2024/11/27

Host: Luis Paz-Ares, MD, PhD Host: Helena Yu, MD Host: Matthew Gubens, MD, MS This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program

en

00:00:00

Guidelines-recommended targeted therapies as...

CME/CE ·

2024/11/27

Host: Luis Paz-Ares, MD, PhD Host: Helena Yu, MD Host: Matthew Gubens, MD, MS This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program

en

00:00:00

Incorporation of guidelines-concordant care for...

CME/CE ·

2024/11/27

Host: Luis Paz-Ares, MD, PhD Host: Helena Yu, MD Host: Matthew Gubens, MD, MS This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program

en

267 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事